文献速递临床试验与 GCP

代谢汤颗粒联合二甲双胍治疗2型糖尿病合并肥胖患者的有效性与安全性:一项随机双盲安慰剂对照多中心临床试验的研究方案

Effectiveness and safety of Daixie Decoction granules combined with metformin for the treatment of T2DM patients with obesity: study protocol for a randomized, double-blinded, placebo-controlled, multicentre clinical trial.
PubMed 文献 · Trials · 2023-04-19

本研究为多中心、随机、双盲、安慰剂对照临床试验,拟纳入符合Nathrow标准的2型糖尿病合并肥胖患者,干预组与对照组各133例,在统一饮食控制和运动治疗基础上分别接受代谢汤颗粒联合二甲双胍或代谢汤颗粒安慰剂联合二甲双胍治疗。所有受试者接受6个月治疗及6个月随访,以HbA1c降低1%和体重降低3%的有效率作为主要结局,旨在评估代谢汤颗粒联合二甲双胍治疗2型糖尿病合并肥胖的有效性和安全性。

要点

  • 代谢汤颗粒联合二甲双胍治疗2型糖尿病合并肥胖的多中心随机双盲安慰剂对照试验方案。
  • 干预组与对照组各133例,治疗6个月、随访6个月,主要结局为HbA1c降低1%和体重降低3%的有效率。
  • 次要结局包括空腹血糖、血脂、C肽、胰岛素、炎症因子、HOMA-IR及MRI测量的上腹部皮下和内脏脂肪含量。

核心结论

  • 研究旨在确定代谢汤颗粒联合二甲双胍治疗2型糖尿病合并肥胖患者的有效性和安全性。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照临床试验。
  • 符合Nathrow标准的受试者随机分为干预组和对照组,每组133例(n1=n2=133)。
  • 在统一饮食控制和运动治疗基础上,干预组接受代谢汤颗粒联合二甲双胍,对照组接受代谢汤颗粒安慰剂联合二甲双胍。
  • 所有受试者接受6个月治疗,随后6个月随访。

关键数值与推荐

  • 主要结局为HbA1c降低1%和体重降低3%的有效率。
  • 次要结局包括空腹血糖、血脂、C肽、胰岛素、炎症因子、胰岛素抵抗指数(HOMA-IR)以及MRI测量的上腹部皮下和内脏脂肪含量。
  • 治疗和随访期间监测血常规、尿常规、便常规、肝肾功能、心电图等安全性指标及主要不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 2 diabetes mellitus (T2DM) with obesity is a glycolipid metabolism disorder, which makes hypoglycaemic treatment more complex and increases the proportion of multidrug combinations. In addition, patients are more prone to adverse reactions and gradually lose compliance with treatment. Previous clinical trials have demonstrated that Daixie Decoction granules (DDG) can reduce body weight and blood lipids and improve the quality of life of T2DM with obesity. But there are a lack of further evaluations for the efficacy and safety of DDG combined with metformin. METHODS/DESIGN: The study is designed as a multicentre, randomized, double-blind, placebo-controlled clinical trial. Participants who meet the Nathrow criteria will be randomly assigned to the intervention group and control group (n 1 = n 2 = 133). Based on a unified diet control and exercise therapy, the intervention group will be treated with DDG and metformin, and the control group will be treated with DDG placebo and metformin. All subjects will receive a 6-month treatment followed by a 6-month follow-up. Effective rate of a 1% decrease in HbA1c and 3% decrease in body weight will serve as the primary outcome. The secondary outcome include fasting plasma glucose, blood lipids, C-peptides, insulin, inflammatory factors, insulin resistance index (HOMA-IR) and the subcutaneous and visceral fat content in the upper abdomen measured by MRI. Blood routine, urine routine, stool routine, liver and kidney function, EKG and other safety indicators and major adverse reactions were monitored during total treatment and follow-up time. DISCUSSION: We aimed to determine the efficacy and safety of DDG combined with metformin for the treatment of T2DM patients with obesity. TRIAL REGISTRATION: Trial registration: ChiCTR, ChiCTR2000036290. Registered 22 August 2014, http://www.chictr.org.cn/showprojen.aspx? proj=59001.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Liu Z, Zhang K, Zhang J, et al. Effectiveness and safety of Daixie Decoction granules combined with metformin for the treatment of T2DM patients with obesity: study protocol for a randomized, double-blinded, placebo-controlled, multicentre clinical trial. Trials. 2023. PMID: 37076915. doi:10.1186/s13063-023-07301-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。